In clinical practice, dose delivery in proton therapy treatment is affected by uncertainties on the range of the beam within the patient, requiring medical physicists to introduce safety margins on the penetration depth of the beam. Although this ensures an irradiation of the entire clinical target volume with the prescribed dose, these safety margins also lead to nearby healthy tissues exposition and subsequent risk of side effects. Therefore, non-invasive techniques enabling margin reduction through on-line monitoring of prompt gammas emitted along the proton tracks in the patient are currently under development. This study reports on the proof-of-concept to use metal-based nanoparticles, injected into tumour, as a prompt gamma enhancer, helping in the beam range verification. It identifies the limitations of this application suggesting a low feasibility in a realistic clinical scenario but opens some avenues for improvement.
Original languageEnglish
Publication statusPublished - 2022
Event68th Annual International Meeting of the Radiation Research Society - Waikoloa, United States
Duration: 16 Oct 202219 Oct 2022


Conference68th Annual International Meeting of the Radiation Research Society
Country/TerritoryUnited States


Dive into the research topics of 'Metallic nanoparticles as proton beam range monitor'. Together they form a unique fingerprint.

Cite this